Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2004

Magro CM, Nuovo G, Ferri C, A Crowson N, Giuggioli D, Sebastiani M. Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma. J Cutan Pathol. 2004;31(1):43-50.

Payne MM, Rader AE, McCarthy DM, Rodgers WH. Merkel cell carcinoma in a malignant pleural effusion: case report. Cytojournal. 2004;1(1):5.

Murphy M, J Carlson A, Keough MP, Claffey KP, Signoretti S, Loda M. Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27. J Cutan Pathol. 2004;31(7):477-82.

Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, et al. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle. Clin Cancer Res. 2004;10(14):4680-7.

Adkins MW, Tyler JK. The histone chaperone Asf1p mediates global chromatin disassembly in vivo. J Biol Chem. 2004;279(50):52069-74.

Zhou P. Determining protein half-lives. Methods Mol Biol. 2004;284:67-77.

Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 2004;5(3):253-61.

Jang B-, Lim K-, Paik J-, Kwon Y-, Shin S-, Kim S-, et al. Up-regulation of human beta-defensin 2 by interleukin-1beta in A549 cells: involvement of PI3K, PKC, p38 MAPK, JNK, and NF-kappaB. Biochem Biophys Res Commun. 2004;320(3):1026-33.

Baron A, Migita T, Tang D, Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem. 2004;91(1):47-53.

Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K, et al. The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J Biol Chem. 2004;279(51):53317-22.